Matt Richtel, a health and science reporter, spent a year chasing the rise of ultra‑potent synthetic drugs for The New York Times’ “New Drug War” series. He tracked a forum user known as Chemical Analyst, a jailed dealer who sold mind‑bending chemicals, and used that insider view to illuminate the market’s dark corners today.

The report links the surge in overdose deaths—from 6,771 in 1971 to 80,000 in 2024—to the proliferation of lab‑made compounds. By interviewing suppliers, clandestine chemists, and even a Chinese manufacturer, Richtel shows how a single operator can import and redistribute potent drugs from China without cartel backing in the market.

During a video tour of Chemical Analyst’s apartment‑turned‑lab, the reporter witnessed a makeshift pharmacy complete with a digital scale, heat sealer and mailing envelopes. The cramped space underscored how easily an individual can assemble a dangerous supply chain, raising alarms for regulators and public‑health officials in the country today again.

Richtel’s work, backed by daily legal reviews and editor oversight, aims to inform policy by exposing the hidden economics of synthetic drugs. The series demonstrates that law enforcement must adapt to a decentralized market where a single dealer can trigger nationwide health crises across the nation and beyond today again.